Journal: Signal Transduction and Targeted Therapy

Article Title: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

doi: 10.1038/s41392-025-02511-5

Figure Lengend Snippet: Neoantigen identification and delivery via oncolytic adenovirus vectors. a Schematic representation of neoantigen identification combining WES and MS. This figure was created via resources from BioRender ( www.biorender.com ). b Design of the neoantigen delivery system. The expression cassette of neoantigen cDNA sequences corresponding to the 29-mer long peptides covering the mutated epitopes was inserted into the E3 region of the survivin promoter (SVP)-regulated oncolytic adenovirus vector Ad5SVPF11 to generate a novel OAV, AdSVP-NAg. C57BL/6 mice inoculated with B16F10 melanoma, MC38 colon carcinoma, or Hep53.4 hepatocellular carcinoma cells were treated with PBS, vector (Ad5SVPF11), SLP, vector combined with SLP, or AdSVP-NAg. Tumor growth curves ( c ) ( n = 6 mice per group), representative images ( d ) of the IFN-γ ELISpot of neoantigen-specific T cells from the spleen in each group and immunofluorescence images ( e ) of tumor tissues. The data are shown as the means ± SDs ( c ) and are representative of two independent experiments ( c – e ). Significance was calculated by two-way ANOVA ( c ). * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: The formulation of the SLP vaccine was adapted from previous studies, with each dose containing 20 μg of each 29-mer neoantigen peptide in Supplementary Table and 50 μg of poly I:C (MedChemExpress, USA), dissolved in 200 μL of a 10% DMSO/90% PBS solution.

Techniques: Expressing, Plasmid Preparation, Enzyme-linked Immunospot, Immunofluorescence